Related Experiment Video
Updated: Jul 16, 2026

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
Human β-Defensin 23 as a Carrier for In Vitro and In Vivo Delivery of mRNA
Kyoung-Ran Kim1, Junghyun Kim1, Seunghye Cho2
1Chemical and Biological Integrative Research Center, Institute of Science and Technology (KIST), Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea.
Abstract:
The successful application of mRNA therapeutics hinges on the effective intracellular delivery of mRNA both in vitro and in vivo. However, this remains a formidable challenge due to the polyanionic nature, longitudinal shape, and low nuclease resistance of mRNA. In this study, we introduce a novel mRNA delivery platform utilizing a human β-defensin peptide, hBD23. The positive charge of hBD23 allows it to form nanocomplexes with mRNA, facilitating cellular uptake and providing protection against serum nucleases. When optimized for peptide-to-mRNA (N/P) ratios, these hBD23/mRNA complexes demonstrated efficient cellular delivery and subsequent protein expression both in vitro and in vivo. Importantly, as hBD23 is human derived, the complexes exhibited minimal cytotoxicity and immunogenicity. Given its high biocompatibility and delivery efficiency, hBD23 represents a promising platform for the in vitro and in vivo delivery of mRNA.
Insights
A novel human peptide, hBD23, effectively delivers messenger RNA (mRNA) into cells. This biocompatible platform enhances mRNA therapeutics by improving cellular uptake and stability, showing promise for in vitro and in vivo applications.
Area of Science:
- Biotechnology
- Molecular Biology
- Drug Delivery Systems
Background:
- Effective intracellular delivery of messenger RNA (mRNA) is crucial for therapeutic applications but faces challenges due to mRNA's polyanionic nature, shape, and susceptibility to nucleases.
- Current delivery methods often struggle with efficiency, stability, and potential toxicity or immunogenicity.
- Developing biocompatible and efficient mRNA delivery vectors remains a significant hurdle in advancing mRNA therapeutics.
Purpose of the Study:
- To introduce and evaluate a novel mRNA delivery platform based on the human β-defensin peptide, hBD23.
- To assess the ability of hBD23/mRNA nanocomplexes to facilitate cellular uptake and protect mRNA from degradation.
- To determine the efficacy and biocompatibility of the hBD23 platform for both in vitro and in vivo mRNA delivery.
Main Methods:
- Formation of nanocomplexes between the positively charged hBD23 peptide and negatively charged mRNA.
- Optimization of peptide-to-mRNA (N/P) ratios to achieve efficient complex formation and delivery.
- In vitro and in vivo studies to evaluate cellular uptake, mRNA protection, protein expression, cytotoxicity, and immunogenicity.
Main Results:
- hBD23 successfully formed nanocomplexes with mRNA, enhancing cellular uptake and providing protection against serum nucleases.
- Optimized hBD23/mRNA complexes demonstrated efficient mRNA delivery and subsequent protein expression in vitro and in vivo.
- The human-derived nature of hBD23 resulted in minimal observed cytotoxicity and immunogenicity.
Conclusions:
- The human β-defensin peptide hBD23 serves as a highly effective and biocompatible platform for mRNA delivery.
- hBD23/mRNA nanocomplexes overcome key challenges in mRNA therapeutics, including cellular uptake and nuclease resistance.
- This novel delivery system holds significant promise for advancing the clinical application of mRNA-based therapies.
More Related Videos
Related Concept Videos
Nuclear Export of mRNA
Regulated mRNA Transport
Leaky Scanning
Nuclear Export of mRNA
Regulated mRNA Transport
Bacterial Translocation and Protein Secretion

